One Study Is Not an Evidence Strategy: Why MedTech Companies Need an Evidence Roadmap

One of the most consequential mistakes I see in medtech evidence generation begins with a question that sounds completely reasonable:

“What study should we conduct?”

It is an important question.

It is rarely the first question a company should ask.

The better question is:

“What decisions will our evidence need to support over the next several years, and in what order?”

That distinction matters because a study is a project. An evidence strategy is a sequence of deliberate investments designed to move a technology from one meaningful decision to the next.

A study may be intended to demonstrate safety, validate clinical performance, support regulatory clearance, establish clinical utility, strengthen a payer discussion, quantify economic value, or reduce uncertainty for health systems. Each objective may be valid, but no single study can be expected to satisfy every stakeholder or answer every question.

The problem begins when leadership treats the next study as an isolated milestone rather than one part of a larger evidence roadmap.

The company focuses on getting the protocol written.

The clinical team focuses on getting sites activated.

The investigators focus on generating credible clinical results.

The regulatory team focuses on meeting the requirements of the applicable pathway.

The commercial team may assume that strong results can later be translated into a reimbursement or adoption story.

Everyone is working hard toward a legitimate objective. But without an evidence roadmap, those efforts may not build on one another as effectively nor efficiently as they should.

What are the risks?

• The regulatory study reaches its endpoint but does not collect the outcomes payers will later request.
• The post-market study produces a publication but uses a comparator that does not reflect the decision hospitals are making.
• The economic model is developed after the clinical program is complete, only for the company to discover that critical resource utilization inputs were never collected.
• The real-world evidence study begins years later than it should because nobody defined which unanswered questions it needed to address.

These are not necessarily failures of science or execution.

They are failures of strategy, of sequencing.

A strong evidence roadmap identifies the decisions ahead, the stakeholders who will make them, the uncertainties preventing action, and the most appropriate opportunity to address each uncertainty.

It does not attempt to place every possible measure into the next protocol.

It determines what must be answered now, what can be answered later, and how each study can make the next one more focused, efficient, and valuable.

Because the goal is not simply to complete the next study.

The goal is to create an evidence program that moves the technology forward.

The Study Is Only One Investment

By the time a medtech company begins discussing a clinical study, significant strategic decisions have often already been made.

The target population may have been defined.

The regulatory pathway may be underway.

Investors may have been given timelines tied to a clinical milestone.

Commercial assumptions may have been built into financial projections.

Prospective customers may already be asking about clinical utility, reimbursement, implementation, or economic value.

The study therefore does not exist in isolation. It sits within a larger series of commitments, expectations, and decisions.

Yet evidence development is often planned one protocol at a time.

The team concentrates on the immediate milestone:

• Complete the feasibility study
• Support a regulatory submission
• Validate clinical performance
• Generate a peer-reviewed publication
• Gather post-market experience
• Prepare for payer engagement
• Demonstrate value to hospitals

Each milestone may be appropriate. The challenge is determining whether the evidence created for one milestone will adequately prepare the company for the next.

A regulatory study may establish that a technology performs as intended, but the subsequent payer discussion may require evidence of clinical utility, comparative value, durability, or medical necessity.

A clinical utility study may show that the technology changes physician decision making, but hospitals may still want to understand workflow, staffing, implementation requirements, and budget impact.

A real-world study may demonstrate favorable outcomes in routine practice, but the analysis may be difficult to interpret if the company did not clearly define the appropriate comparator or patient population.

When these needs are identified sequentially rather than strategically, the company may find itself repeatedly returning to evidence generation to answer questions that could have been anticipated much earlier.

The organization does not necessarily spend too little on evidence.

It may spend substantially more than expected because each study was planned without sufficient consideration of the one that would follow.

The Evidence Roadmap

An evidence roadmap connects a company’s clinical, regulatory, reimbursement, market access, and commercialization objectives over time.

It starts with the decisions the organization expects to face.

For each decision, the company should identify:

• Who will make the decision?
• What does that stakeholder need to believe?
• What uncertainty could prevent action?
• What evidence is already available?
• What evidence is still missing?
• Which study design is best suited to close that gap?
• When will the evidence be needed?
• What data can be collected now to improve a later study or analysis?

The answers will be different for every technology.

A diagnostic company may need to progress from analytical validity to clinical validity, clinical utility, patient outcomes, economic value, and payer coverage.

A therapeutic device company may need to establish safety and performance, comparative effectiveness, durability, appropriate patient selection, resource utilization, and implementation feasibility.

A digital health company may need to demonstrate engagement, clinical effect, integration into existing workflows, generalizability, scalability, and financial value.

The roadmap translates these broad needs into a deliberate sequence.

That sequence might include a feasibility study followed by a regulatory study, a prospective clinical utility study, a real-world outcomes analysis, and an economic evaluation.

In another program, the company may be able to incorporate selected patient-reported outcomes, utilization measures, and workflow data into a study already being planned, reducing the need for a separate prospective effort.

The roadmap does not prescribe a standard number of studies.

It creates a strategic rationale for why each study exists, what decision it supports, and how it prepares the organization for what comes next.

The Sequence Matters

Evidence questions are not interchangeable, and they do not always need to be answered at the same time.

Timing matters.

A company may need to demonstrate basic clinical performance before it can credibly study broader clinical utility. It may need a clearer definition of the treated population before estimating economic value. It may need sufficient real-world use before evaluating durability or implementation across diverse settings.

But some evidence should be considered earlier than companies expect.

If the future value proposition depends on avoiding procedures, reducing length of stay, decreasing staff burden, or improving patient experience, the company should determine when those outcomes can first be measured credibly.

If the payer strategy depends on identifying a specific patient subgroup, the study population and analysis plan should begin building that case before coverage discussions start.

If a future budget impact model will rely on resource utilization data, the company should identify those inputs before completing the clinical studies that offer the best opportunity to collect them.

Evidence sequencing is not about prematurely answering every downstream question.

It is about avoiding unnecessary dead ends.

Every study should either answer an important question, improve the design of the next study, reduce uncertainty around the next investment, or create an evidence asset that can support future decisions.

The most valuable studies often accomplish several of these goals at once.

Where Companies Usually Go Wrong

Most medtech companies understand that evidence needs will evolve.

The challenge is that the evolution is often managed reactively.

A regulatory milestone is achieved, and then the company begins planning for reimbursement.

Coverage challenges emerge, and then the company starts considering health economic evidence.

Hospitals raise concerns about implementation, and then the team looks for workflow data.

Physicians ask which patients benefit most, and then the company revisits subgroup analyses that were not adequately powered or prespecified.

Investors ask how the evidence reduces commercial risk, and leadership realizes that the completed study answered a narrower question than the organization had communicated.

This progression can feel natural because each new milestone brings different stakeholders into the conversation.

But it also means critical perspectives are introduced after the most useful opportunity to influence the evidence plan has passed.

Market access should not begin when the company is ready to meet with payers.

Health economics should not begin when someone decides a budget impact model is needed.

Real-world evidence should not begin as a general effort to collect more data after commercialization.

Commercial planning should not begin once the regulatory program is complete.

These disciplines should inform the roadmap early enough to identify which questions belong in which phase of development.

The Studies Were Strong. The Program Was Fragmented.

I have reviewed medtech programs in which each individual study appeared credible.

The feasibility study produced encouraging results.

The regulatory study met its primary endpoint.

The clinical team secured respected investigators.

The findings were presented at a conference and prepared for publication.

A post-market study was then initiated to gather additional experience.

Viewed separately, the studies were reasonable.

Viewed together, they did not create a coherent evidence story.

The patient populations differed enough to make comparisons difficult.

The endpoints changed from one study to the next.

The comparator used in the clinical program did not reflect the alternative that payers and hospitals considered most relevant.

Resource utilization was collected inconsistently.

Patient-reported outcomes were introduced too late to establish a meaningful baseline.

The post-market study gathered more clinical data without addressing the specific uncertainty preventing adoption.

The issue was not that the company lacked studies.

It lacked a connected evidence program.

A collection of studies does not automatically become an evidence strategy. The studies must build toward a defined set of decisions.

Without that connection, companies may accumulate data without meaningfully reducing commercial uncertainty.

The Questions That Shape the Roadmap

A useful evidence roadmap begins with the decisions ahead rather than the study designs the company already knows how to conduct.

Leadership teams should ask:

• What is the next decision that matters to the company?
• Which stakeholder controls that decision?
• What evidence will that stakeholder expect?
• What uncertainty is most likely to delay or prevent action?
• Which outcomes must be measured prospectively?
• Which questions can appropriately be addressed through real-world data?
• Which economic inputs should be collected during clinical research?
• Which patient population will define the intended-use and covered populations?
• Which comparator reflects the real clinical and commercial decision?
• How will the current study inform the design of the next?
• When will each evidence asset be needed?
• What happens if the company waits to answer the question?

These questions often reveal that the next evidence need is not simply “another study.”

The company may need a reimbursement landscape assessment before finalizing the protocol.

It may need stakeholder research to understand why hospitals remain hesitant.

It may need an evidence gap analysis to distinguish what has already been demonstrated from what is still assumed.

It may need an economic model to identify which variables have the greatest influence on value and should therefore be measured prospectively.

It may need a pragmatic study, database analysis, qualitative study, or implementation assessment rather than another traditional clinical trial.

The roadmap helps the company select the appropriate evidence method for the decision instead of defaulting to the most familiar study design.

More Evidence Does Not Automatically Create More Value

When commercial progress is slower than expected, the instinct is often to generate more evidence.

But more evidence is not always the answer.

A company may conduct another clinical study only to reproduce a finding that stakeholders already accept.

It may collect a large volume of real-world data without defining the decision the analysis should inform.

It may add endpoints that increase site burden and cost without materially strengthening the value proposition.

It may commission an economic model before credible clinical and utilization inputs are available.

It may pursue publication without determining how the publication fits into payer, provider, or health system engagement.

The relevant question is not:

“How much evidence do we have?”

It is:

“What important uncertainty does our evidence resolve?”

Evidence creates value when it helps someone make a decision.

That may be a regulator determining whether the technology meets applicable requirements.

It may be a payer deciding whether the evidence supports coverage for a defined population.

It may be a physician determining whether the technology changes care in a clinically meaningful way.

It may be a health system evaluating whether adoption is operationally and financially justified.

It may be an investor deciding whether the company has reduced the risks associated with commercialization.

An evidence roadmap keeps the program focused on those decisions.

Every Study Should Strengthen the Next One

One of the most important principles of evidence sequencing is that every study should create a stronger foundation for what follows.

An early study may help refine the population most likely to benefit.

It may identify the most credible comparator.

It may clarify which outcomes are clinically meaningful and feasible to collect.

It may reveal site-level implementation barriers that should be addressed before a larger study.

It may estimate effect sizes needed for future sample-size calculations.

It may test the availability and quality of healthcare utilization data.

It may identify patient-reported outcomes that better reflect the burden of disease or treatment.

It may provide inputs for an early economic model that, in turn, identifies the variables that matter most in the next clinical study.

This creates a productive cycle.

Clinical evidence improves the economic analysis.

The economic analysis identifies important evidence gaps.

Stakeholder research clarifies which gaps matter most.

Real-world data help test whether the clinical findings translate into routine practice.

Implementation research explains why results may vary across sites.

Together, these activities create a more credible and useful evidence story.

The objective is not to make each study larger.

It is to make each study more strategically connected.

What Most Leadership Teams Do Not Realize

Evidence sequencing is also a capital-allocation discipline.

Every study competes for limited time, funding, staff attention, investigator engagement, and patient access.

A poorly sequenced study does more than produce incomplete evidence. It consumes resources that may no longer be available when a more important question emerges.

Leadership teams therefore need to evaluate evidence investments with the same rigor applied to other major business decisions.

What milestone does this study support?

What risk will it reduce?

What becomes possible if the results are positive?

What uncertainty will remain?

What is the likely next study?

What should be collected now because it will be expensive or impossible to reconstruct later?

How does this investment strengthen reimbursement, adoption, clinical use, investor confidence, or future research?

These are not questions for the clinical team alone.

They require input from clinical, statistical, operational, regulatory, reimbursement, health economic, market access, and commercial experts.

A strategic CRO should help bring those perspectives together before the protocol and budget become difficult to change.

Study execution remains essential.

But an efficiently executed study is only valuable if it occupies the right place in the evidence sequence.

What Companies Realize Too Late

The absence of an evidence roadmap often becomes visible at the least convenient moment.

The company is preparing for payer discussions and realizes the study population does not align with the population for which coverage will be requested.

The economic model is underway and the team discovers that important utilization data were never collected.

A health system requests evidence of workflow improvement, but workflow was discussed only anecdotally.

The company plans a real-world study but lacks a clearly documented baseline or appropriate comparator.

A publication demonstrates a statistically significant effect, but the outcome does not translate easily into a value message.

A promising subgroup emerges after the analysis, but the study was not designed to evaluate it credibly.

The next financing milestone depends on demonstrating commercial readiness, but the evidence plan supports only a regulatory achievement.

At that point, the organization may need to revise its commercial expectations, rely on assumptions, conduct additional analyses, or invest in another study.

In some cases, additional evidence generation is appropriate and unavoidable.

But in others, the gap exists because the company did not look far enough ahead when an earlier study was being designed.

The cost of that missed opportunity is not limited to the next research budget.

It can affect:

• Time to coverage
• Hospital adoption
• Provider confidence
• Patient access
• Commercial forecasting
• Investor confidence
• Negotiating leverage
• Competitive position
• The company’s ability to finance the next stage of development

An evidence roadmap cannot eliminate every future uncertainty.

It can help the company identify the most predictable uncertainties early enough to act.

Why This Matters Now

Medtech companies are being asked to accomplish more with every evidence investment.

Capital remains selective.

Commercial timelines remain aggressive.

Payers expect clearer demonstrations of medical necessity, comparative value, and relevance to covered populations.

Health systems are evaluating clinical benefit alongside staffing, workflow, implementation, supply chain, budget impact, and competing organizational priorities.

Providers want to understand how a technology fits into an established care pathway and which patients are most likely to benefit.

Patients expect technologies to improve outcomes and experiences that matter in their everyday lives.

Investors want evidence that reduces the risks between regulatory progress and meaningful commercial use.

These expectations cannot be met through disconnected studies planned one milestone at a time.

Companies need a program that connects early clinical learning to regulatory evidence, clinical utility, economic value, real-world performance, implementation, reimbursement, and adoption.

That does not mean every company needs a large, expensive, multiyear research program mapped in perfect detail.

Early-stage companies will continue to face uncertainty.

Technologies will evolve.

Regulatory requirements may change.

New competitors will enter the market.

Commercial assumptions will be tested.

The roadmap should therefore be a living strategy, reviewed as new evidence and stakeholder insights become available.

The objective is not to predict every future study.

It is to maintain a clear view of the decisions ahead and ensure that today’s evidence investment does not make tomorrow’s decision unnecessarily difficult.

TTi’s Perspective

At TTi, we believe evidence planning should begin with the full path the technology must travel, not simply the next protocol that must be written.

Clinical, regulatory, statistical, operational, reimbursement, health economic, and commercial perspectives all have an important role in that process.

Founders and leadership teams understand the company’s vision, financing needs, strategic milestones, and long-term objectives.

Clinical investigators understand patient care, clinical relevance, disease progression, study feasibility, and the realities of practice.

Regulatory experts understand the applicable pathway and the evidence required to meet regulatory expectations.

Biostatisticians bring rigor to study design, endpoint selection, sample-size planning, analysis, and interpretation.

Market access and reimbursement experts understand how payers, providers, and health systems evaluate coverage, payment, value, and adoption.

Health economists help connect clinical outcomes to resource utilization, budget impact, patient burden, and total cost of care.

Operational experts understand what sites can realistically implement and what information can be collected reliably without compromising study execution.

What our team adds is an integrated evidence sequencing and commercialization lens.

We help medtech companies determine which decisions matter next, what evidence those decisions require, and how each study can support the immediate milestone while creating a stronger foundation for the one that follows.

Sometimes that means incorporating selected economic, patient-reported, workflow, implementation, or resource utilization measures into a planned clinical study.

Sometimes it means keeping the current protocol focused and developing a separate real-world or clinical-economic study for the next stage.

Sometimes it means using stakeholder research, evidence synthesis, or early modeling to clarify which outcomes matter before the company commits to a larger investment.

Sometimes it means reconsidering the study population, comparator, sites, follow-up period, data source, or statistical analysis plan.

And sometimes it means deciding that another study is not yet the right next step.

The goal is not to generate the greatest possible volume of evidence.

The goal is to generate the right evidence, in the right sequence, to support the decisions that determine whether the technology reaches the patients who may benefit from it.

Remember:

Evidence becomes a strategy when every study prepares you for the next decision.

– Dr. April

Before You Launch Your Next Study

Ask yourself one question:

Is this study an isolated project, or is it deliberately preparing the company for the next decision?

Our team helps medtech companies develop evidence roadmaps that connect clinical research with regulatory progress, reimbursement, economic value, provider adoption, patient access, and commercialization.

We assess the evidence already available, identify the uncertainties that matter most, define the stakeholders who must act, and determine which questions should be addressed now and which belong in a later stage of the program.

We also help companies evaluate whether planned studies are collecting the outcomes, comparator data, patient insights, resource utilization measures, and implementation information that future decisions may require.

The objective is not to make every study answer every question.

It is to ensure that each evidence investment has a clear purpose, supports a meaningful decision, and strengthens the path ahead.

Because one successful study can move a company forward.

But a connected evidence strategy is what helps a technology move from clinical promise to coverage, adoption, and meaningful patient use.